- Strategies to supercharge cell line productivity using genome editing and smart screening
- How intensified upstream processing—like perfusion and automation—boosts yield, consistency, and compliance
- Methods for leveraging production to deliver customized solutions and in-process quality control
- Cell line development scientists and upstream process engineers
- Bioprocess development managers, molecular biologists, and fermentation specialists
- R&D directors, QA/QC managers, and technology evaluation leads
- Manufacturing operations supervisors and analytical chemists
- Solution providers supporting advanced cell culture and upstream technologies
Cell Line Development & Upstream Bioprocessing
Tomorrow’s Biologics: Innovation, Intensification, and Precision in Cell Line & Upstream Processing
About the event
Join leading cell line scientists, upstream process engineers, and biomanufacturing innovators for this virtual event exploring the latest breakthroughs in cell line development and upstream bioprocessing. Discover how next-generation genome editing, intensified perfusion platforms, and precision batch processing are transforming productivity, scalability, and product quality in biologics and advanced therapies.
What You Will Learn
Who Should Join
Agenda
KOL: Xiaoyan Tang
02/18/2026 11:00 AM - 12:00 PM EST
A Deep-well-plate Enabled Automated High-Throughput Cell Line Development Platform
Join leading cell line scientists, upstream process engineers, and biomanufacturing innovators for this virtual event exploring the latest breakthroughs in cell line development and upstream bioprocessing. Discover how next-generation genome editing, intensified perfusion platforms, and precision batch processing are transforming productivity, scalability, and product quality in biologics and advanced therapies.
KOL: Tom Kelly
02/18/2026 12:30 PM - 1:30 PM EST
When will we have a clone? An industry perspective on the typical CLD timeline
Cell line development (CLD) represents a complex but highly critical process during the development of a biological drug. To shed light on this crucial workflow, a team of BioPhorum members (authors) has developed and executed surveys focused on the activities and effort involved in a typical CLD campaign. An average of 27 members from different companies that participate in the BioPhorum CLD working group answered surveys covering three distinguishable stages of a standard CLD process: (1) Pre-transfection, including vector design and construction; (2) Transfection, spanning the initial introduction of vector into cells and subsequent selection and analysis of the pools; and (3) Single Cell Cloning and Lead Clone Selection, comprising methods of isolating single cells and confirming clonal origin, subsequent expansion and screening processes, and methods for identifying and banking lead clones. The surveys were very extensive, including a total of 341 questions split between antibody and complex molecule CLD processes. In this survey review, the authors interpret and highlight responses for antibody development and, where relevant, contrast complex molecule development challenges to provide a comprehensive industry perspective on the typical time and effort required to develop a CHO production cell line.